Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Research & Development (2016 - 2025)

Historic Research & Development for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Q3 2025 value amounting to $86.3 million.

  • Viridian Therapeutics, Inc.\DE's Research & Development rose 2473.03% to $86.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $321.7 million, marking a year-over-year increase of 5703.14%. This contributed to the annual value of $238.3 million for FY2024, which is 4912.78% up from last year.
  • As of Q3 2025, Viridian Therapeutics, Inc.\DE's Research & Development stood at $86.3 million, which was up 2473.03% from $86.6 million recorded in Q2 2025.
  • Viridian Therapeutics, Inc.\DE's 5-year Research & Development high stood at $86.6 million for Q2 2025, and its period low was $8.1 million during Q3 2021.
  • Its 5-year average for Research & Development is $42.4 million, with a median of $39.3 million in 2022.
  • As far as peak fluctuations go, Viridian Therapeutics, Inc.\DE's Research & Development skyrocketed by 22755.47% in 2021, and later tumbled by 1930.63% in 2024.
  • Viridian Therapeutics, Inc.\DE's Research & Development (Quarter) stood at $22.4 million in 2021, then soared by 75.57% to $39.3 million in 2022, then dropped by 1.93% to $38.6 million in 2023, then soared by 86.63% to $72.0 million in 2024, then grew by 19.87% to $86.3 million in 2025.
  • Its last three reported values are $86.3 million in Q3 2025, $86.6 million for Q2 2025, and $76.8 million during Q1 2025.